TransCode Therapeutics Inc. (RNAZ): Broker Consensus Forecast
TransCode Therapeutics (RNAZ) is developing advanced RNA drug delivery systems for cancer cells, which will grant the company full pricing power following certification. This price chart, where the indicator is fixed at 278.70, confirms the business's autonomy from economic cycles and GDP. Strict FDA regulations, patent protection, and colossal medical testing costs create a high barrier to entry.
Metric breakdowns and analytics for TransCode Therapeutics (RNAZ)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio transcodetherapeutics.com|RNAZ - Company Aggregate Debts|Debts to Book Capitalization TransCode|RNAZ - Company Long-Term Liabilities|Amount of Current Liabilities TransCode Therapeutics|Intermediate Coverage Ratio transcodetherapeutics.com
- company profitability and valuation multiples indicators:
RNAZ - Net Profit|Projected Future Earnings TransCode Therapeutics|RNAZ - Price to Earnings Ratio|Price to Future Earnings Ratio transcodetherapeutics.com|RNAZ - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio TransCode|RNAZ - Operating profit EBITDA|Net earnings per share for the last 12 months TransCode Therapeutics|RNAZ - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months transcodetherapeutics.com|RNAZ - Earnings growth in current year|Projected earnings per share growth rate for next year TransCode Therapeutics
General company analysis:RNAZ TransCode Therapeutics Inc.
This indicator reflects the aggregated fair value of the asset, calculated by benchmarking individual expert forecasts against median industry targets to assess market positioning. By analyzing the historical trend of the consensus target price, an investor can track how the development success of TTX-MC138 nanoparticles for combating distant metastases influences the revision of the fundamental value of TransCode Therapeutics (RNAZ) shares.
Who TransCode Therapeutics competes with
TEM (tempus.com) - Fair Value Consensus|Price Target Chart Qiagen QGEN|IONS: Broker Consensus Forecast|Repligen Corp. - Analyst Consensus Forecast|RNA - Analyst Consensus Forecast|CRSP (CRISPR Therapeutics AG) - Consensus Target|Forecast Levels Chart WGS (genedx.com)|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|STOK: Consensus Target|BioLife Solutions Inc - Analyst Forecast Prices|Wave Life Sciences Corp (WVE) - Price Target Chart|Maze Therapeutics Corp - Fair Value Consensus|SION (Sionna Therapeutics Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast primemedicine.com|Price Target Chart Taysha Gene Therapies, Inc. (TSHA)|uniQure NV - Broker Consensus Forecast|Price Target Chart MeiraGTx PLC MGTX|Analyst Median Target REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Analyst Consensus Forecast|ocugen.com (OCGN) - Consensus Target|PacBio (PACB) - Price Target Chart|Average Forecast Price Benitec Biopharma Inc (BNTC)|DSGN (Design Pharma) - Analyst Consensus Forecast|Broker Consensus Forecast RCKT (Rocket Corp)|Analyst Consensus Forecast FDMT|LXEO - Average Forecast Price|Korro Bio - Consensus Target|Fair Value Consensus EDIT|SLN: Consensus Target|ProQR Therapeutics N.V. - Analyst Forecast Prices|CDXS: Analyst Consensus Forecast|sangamo.com - Fair Value Consensus|NAUT (Nautilus Biotechnology, Inc.) - Analyst Consensus Forecast|Average Forecast Price Metagenomi Inc. MGX|Price Target Chart Precision BioSciences (DTIL)|GBIO (generationbio.com) - Fair Value Consensus|Analyst Consensus Forecast BOLD (Boundless Bio, Inc.)|Analyst Consensus Forecast Exicure Inc. XCUR|IMNN - Price Target Chart|Forecast Levels Chart PHIO|MBIO: Analyst Consensus Forecast|Average Forecast Price Bionano Genomics (BNGO)|Consensus Target APDN|Analyst Consensus Forecast bluebirdbio.com|Consensus Target IPA (ImmunoPrecise Antibodies)|Analyst Forecast Prices OMGA|Analyst Consensus Forecast OMIC (Singular Genomics Systems Inc)|Analyst Median Target Regulus (RGLS)|Syros Pharmaceuticals - Analyst Consensus Forecast|telesisbio.com (TBIO) - Consensus Target|TRACON Pharmaceuticals, Inc. (TCON) - Price Target Chart|UBX - Analyst Median Target
